AR088845A1 - Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel - Google Patents

Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel

Info

Publication number
AR088845A1
AR088845A1 ARP120104260A ARP120104260A AR088845A1 AR 088845 A1 AR088845 A1 AR 088845A1 AR P120104260 A ARP120104260 A AR P120104260A AR P120104260 A ARP120104260 A AR P120104260A AR 088845 A1 AR088845 A1 AR 088845A1
Authority
AR
Argentina
Prior art keywords
tetrahydro
quinoline
treatment
skin diseases
ilmetil
Prior art date
Application number
ARP120104260A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088845(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR088845A1 publication Critical patent/AR088845A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Método para el tratamiento de las enfermedades de la piel y de las afecciones de la piel en un paciente en necesidad del mismo que comprende la administración de una cantidad terapéuticamente eficaz de una composición farmacéutica que contiene una cantidad terapéuticamente eficaz de 7-(1H-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina, o sus enantiómeros individuales, o los tautómeros de la misma, o una sal farmacéuticamente aceptable de la misma.
ARP120104260A 2011-11-10 2012-11-12 Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel AR088845A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10

Publications (1)

Publication Number Publication Date
AR088845A1 true AR088845A1 (es) 2014-07-10

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104260A AR088845A1 (es) 2011-11-10 2012-11-12 Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel

Country Status (21)

Country Link
US (4) US20130123303A1 (es)
EP (3) EP2776034B1 (es)
JP (2) JP6359456B2 (es)
KR (1) KR102004563B1 (es)
CN (1) CN104136029A (es)
AR (1) AR088845A1 (es)
AU (2) AU2012335803B2 (es)
BR (1) BR112014011336A2 (es)
CA (1) CA2855005C (es)
CL (1) CL2014001242A1 (es)
DK (1) DK2776034T3 (es)
ES (1) ES2635421T3 (es)
IL (3) IL232483B (es)
MX (1) MX350662B (es)
MY (1) MY182553A (es)
RU (2) RU2630978C2 (es)
SG (3) SG10201809506TA (es)
TW (3) TW202014189A (es)
UA (1) UA109359C2 (es)
WO (1) WO2013070861A1 (es)
ZA (1) ZA201403396B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CA2911472A1 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69940227D1 (de) * 1998-05-08 2009-02-12 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
ZA200604403B (en) * 2003-11-20 2007-09-26 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CN101426502A (zh) * 2004-05-25 2009-05-06 桑斯罗萨医药发展公司 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) * 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
US8455548B2 (en) * 2007-10-18 2013-06-04 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
EP2320911B1 (en) * 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
CA2779063A1 (en) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8513247B2 (en) * 2010-03-26 2013-08-20 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
AU2011231544B2 (en) * 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
EP2600832A1 (en) * 2010-08-06 2013-06-12 Galderma Research & Development Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
EP3763370A1 (en) 2021-01-13
RU2630978C2 (ru) 2017-09-15
MY182553A (en) 2021-01-25
CL2014001242A1 (es) 2014-11-14
KR20140107237A (ko) 2014-09-04
RU2014122758A (ru) 2015-12-20
AU2012335803B2 (en) 2016-05-26
IL232483B (en) 2018-10-31
IL232483A0 (en) 2014-06-30
JP6526737B2 (ja) 2019-06-05
CA2855005C (en) 2016-11-22
SG10201809506TA (en) 2018-11-29
EP2776034B1 (en) 2017-03-22
EP3184110A1 (en) 2017-06-28
TW202014189A (zh) 2020-04-16
US20160051534A1 (en) 2016-02-25
SG10201609145PA (en) 2016-12-29
SG11201402246RA (en) 2014-06-27
NZ624771A (en) 2016-11-25
KR102004563B1 (ko) 2019-07-26
ES2635421T3 (es) 2017-10-03
BR112014011336A2 (pt) 2017-05-02
US20150231128A1 (en) 2015-08-20
AU2012335803A1 (en) 2014-05-29
AU2016216627A1 (en) 2016-09-08
UA109359C2 (xx) 2015-08-10
JP6359456B2 (ja) 2018-07-18
MX2014005640A (es) 2014-09-22
CA2855005A1 (en) 2013-05-16
EP3184110B1 (en) 2020-10-07
US20170095466A1 (en) 2017-04-06
IL268757A (en) 2019-10-31
TWI580424B (zh) 2017-05-01
EP2776034A1 (en) 2014-09-17
TWI708604B (zh) 2020-11-01
TW201713338A (zh) 2017-04-16
RU2667645C1 (ru) 2018-09-21
CN104136029A (zh) 2014-11-05
US9308201B2 (en) 2016-04-12
TW201328694A (zh) 2013-07-16
JP2017149767A (ja) 2017-08-31
AU2016216627B2 (en) 2017-10-19
ZA201403396B (en) 2015-07-29
DK2776034T3 (en) 2017-07-10
US20130123303A1 (en) 2013-05-16
MX350662B (es) 2017-09-13
WO2013070861A1 (en) 2013-05-16
IL261269A (en) 2018-10-31
JP2014533271A (ja) 2014-12-11

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
ECSP12011834A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos.
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
DOP2013000314A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
UY36123A (es) Derivados de carboxamida
CR20160527A (es) Derivados de carboxamida
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
UY37745A (es) Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
AR100153A1 (es) Medicamento
EA201200799A1 (ru) Гепатопротекторное средство

Legal Events

Date Code Title Description
FB Suspension of granting procedure